[A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].

We conducted a multicenter early phase II study to evaluate the feasibility and therapeutic efficacy of high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (auto-PBSCT) for the treatment of intermediate grade non-Hodgkin's lymphoma (IG-NHL). High-dose etoposide or cyclophosphamide followed by G-CSF was used for PBSC mobilization, and a sufficient number of CD34+ cells (> 1 x 10(6)/kg) were collected. Out of 81 enrolled patients, 50 received high-dose chemotherapy with auto-PBSCT; Hematologic recovery after transplantation was rapid. The incidence of grade III/IV toxicity (Bearman) was about 6%; treatment-related mortality was 6% (3/50). The Disease-free survival rate for the patients in complete remission who received high-dose chemotherapy with auto-PBSCT was better than that for the patients who were treated with conventional chemotherapy (57% vs 35%). These preliminary results indicated that high-dose chemotherapy with auto-PBSCT is feasible and effective. A prospective randomized phase III clinical trial will be required to assess the efficacy of high-dose chemotherapy with auto-PBSCT as a post-remission therapy for IG-NHL.
AuthorsT Chou, T Ishiguro, K Imajo, F Kawano, H Gondo, M Kasai, M Masuda, M Koike, C Shimazaki, M Hara, K Shinagawa, M Ogawa, F Takaku, M Harada
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 40 Issue 10 Pg. 1058-67 (Oct 1999) ISSN: 0485-1439 [Print] JAPAN
PMID10565222 (Publication Type: Clinical Trial, Clinical Trial, Phase II, English Abstract, Journal Article, Multicenter Study)
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Lymphoma, Non-Hodgkin (therapy)
  • Male
  • Middle Aged
  • Transplantation, Autologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: